Panel Discussion: Aligning with Physicians, Payers, & Regulators to Strengthen an Integrated Roadmap for Drug– Diagnostic Value & Access
- What is the biggest barrier each stakeholder sees when drugs and diagnostics are developed or evaluated in silos, and how do we overcome these disconnects?
- When Rx-Dx don’t launch together, what are the downstream consequences for physicians, patients, and payers, and how can these be prevented?
- What lessons from HER2, EGFR, and PD-L1 can we apply today, and what pitfalls must be avoided as we move toward more complex biomarkers like multimodal and AI-driven diagnostics?